This article is more than 5 years old. Information may no longer be current.
Cefuroxime may protect vision in addition to preventing endophthalmitis
Click Here to Manage Email Alerts
BERLIN — Intracameral cefuroxime may not only protect patients against endophthalmitis, but may also protect final visual acuity in the case of infection, one expert said here.
 Peter Barry |
Peter Barry, FRCS, discussed visual results from the European Society of Cataract and Refractive Surgeons Endophthalmitis Study Group at the ESCRS annual meeting.
In the four groups, four staphylococcal and five streptococcal cases developed without any periocular antibiotic; four staphylococcal and three streptococcal cases developed under topical antibiotic drops without injection; two staphylococcal cases developed with intracameral cefuroxime and placebo drops; and one staphylococcal infection developed under intracameral cefuroxime and levofloxacin.
Final visual acuity range in the 11 staphylococcal cases was 20/80 to 20/20, and no cases were declared legally blind. Final visual acuity for the eight streptococcal cases was 20/20 to no light perception with five cases declared legally blind.
"None of these five have received cefuroxime. So not only does cefuroxime reduce your incidence of endophthalmitis, but if you're unfortunate enough to get it, it seems to protect your ultimate visual outcome," Dr. Barry said.